Century Therapeutics IPSC
NASDAQ IPSC
$1.58 -0.03 (-1.86%)
At close: Oct 22, 2026 · 4:00 PM EDT

Century Therapeutics (IPSC) EBIT Margin (2022 - 2025)

Updated

Century Therapeutics' EBIT Margin was -15.82% in FY2025, up 2080.66 percentage points from -2096.48% in FY2024.

Analysis

Century Therapeutics (IPSC) EBIT Margin (2022 - 2025) Analysis & Trends

From FY2022 onward, Century Therapeutics has reported EBIT Margin for 4 years.

  • EBIT Margin shows a three-year change of +2558.35 percentage points (FY2022 to FY2025).
  • Per Business Quant data, EBIT Margin in earlier years was -2096.48% in FY2024 (+4460.39 pp), -6556.87% in FY2023 (-3982.70 pp) and -2574.17% in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn 24.35%
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn 37.86%
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn -3.52%
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn 32.97%
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn 20.57%
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn 34.95%
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn -133.21%
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn 28.37%
10 Century Therapeutics 322.04 Mn -182.34 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 67.95%
Dec 31, 2024 -893.46%
Sep 30, 2024 -4,398.10%
Jun 30, 2024 -4,507.78%
Mar 31, 2024 -3,661.87%
Dec 31, 2023 -16,329.10%
Sep 30, 2023 -24,071.62%
Jun 30, 2023 -35,431.31%
Mar 31, 2023 -1,865.17%
Dec 31, 2022 -6,392.71%
Sep 30, 2022 -1,427.07%
Jun 30, 2022 -2,245.77%
Mar 31, 2022 -3,538.37%
API Access

Century Therapeutics EBIT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit-margin&ticker=IPSC&period=max&api_key=YOUR_API_KEY